Prestige Consumer Healthcare Inc. — Form 10-Q Summary
Reporting period: Fiscal 2023 first quarter, the three months ended June 30, 2022; comparisons are with the three months ended June 30, 2021. The company develops, manufactures, markets and distributes over-the-counter healthcare products in North America and international markets.
Financial performance
| Metric | Q1 FY2023 | Q1 FY2022 | Change |
|---|---|---|---|
| Total revenue | $277.1 million | $269.2 million | +2.9% |
| Gross profit / margin | $160.1 million / 57.8% | $159.0 million / 59.1% | +$1.1 million; margin down 1.3 percentage points |
| Operating income | $87.0 million | $91.3 million | Down 4.7% |
| Net income | $55.3 million | $57.8 million | Down 4.3% |
| Diluted EPS | $1.09 | $1.14 | Down 4.4% |
| Operating cash flow | $58.2 million | $69.3 million | Down $11.1 million |
| Capital expenditures | $1.0 million | $1.5 million | Down $0.5 million |
Gross margin pressure primarily reflected higher supply-chain costs and product mix. Operating expenses rose to $73.1 million from $67.7 million, including higher general and administrative costs, primarily compensation and professional fees. Net interest expense was $15.3 million versus $15.1 million. The effective tax rate fell to 22.0% from 24.4%, mainly due to discrete share-based compensation items.
Segments and material changes
- North American OTC Healthcare: Revenue was $242.5 million, essentially unchanged year over year. Cough and cold revenue increased 53.7%, while analgesics declined 15.3%; segment contribution margin fell to $104.2 million from $107.8 million.
- International OTC Healthcare: Revenue rose 28.9% to $34.5 million, primarily on Australian Hydralyte sales following easing COVID-19 restrictions and increased consumer illnesses. Contribution margin increased to $16.0 million from $11.8 million.
- Consolidated operating income and earnings declined despite higher revenue, reflecting margin compression and higher operating expenses. The prior-year comparison included demand spikes in certain COVID-affected categories; the current quarter also benefited from brands acquired from Akorn in July 2021.
Cash, debt and liquidity
- Cash and cash equivalents were $35.9 million at June 30, 2022, up $8.7 million from March 31, 2022.
- Long-term debt, net, was $1.472 billion; gross borrowings were $1.490 billion, including $10.0 million drawn on the ABL revolver. Revolver availability was $137.5 million. The company made a voluntary $15.0 million term-loan repayment during the quarter.
- Financing activities used $47.4 million, including $37.7 million of purchases under the share repurchase program. The program authorized up to $50.0 million through May 2023.
- Management said operating cash flow and existing credit facilities should cover working capital and capital expenditures for the next 12 months, excluding acquisitions. The company reported compliance with applicable debt covenants and anticipated continued compliance.
Outlook, risks and unusual items
- No quantified revenue or earnings guidance is provided. Management described continued uncertainty from inflation, global supply constraints, labor shortages, the pandemic and geopolitical instability. These conditions could pressure demand, pricing, costs, and product availability; the company reported no material overall supply-chain disruption to date.
- Approximately $490 million of debt carried variable interest rates. A 1 percentage-point rate increase was estimated to reduce quarterly pre-tax earnings and cash flow by about $1.2 million, all else equal.
- Walmart represented 19.9% of gross revenue in the quarter; the five largest brands represented approximately 41.5%. The company also relies on third-party manufacturers and a third-party distribution operation.
- Currency translation adjustments reduced other comprehensive income by $9.5 million; total other comprehensive loss was $10.3 million. The U.S. qualified pension plan termination settlements produced a $0.4 million settlement loss, funded with plan assets.
- Goodwill and intangible assets totaled approximately $3.26 billion. Management reported no impairment indicators at June 30, 2022; future impairment risk depends on operating performance and valuation assumptions. Routine legal matters were not expected to have a material adverse effect, taking recorded reserves into account.
Important facts for investors to verify
- Whether higher input, shipping and labor costs continue to compress gross margins, and whether pricing or product mix offsets them.
- Whether international growth, particularly Hydralyte, is sustained and North American category trends improve.
- Working-capital needs and operating cash flow, including the effect of inventory growth and receivables.
- Debt, variable-rate exposure, covenant headroom and remaining repurchase authorization.
- Customer and supplier concentration, supply-chain continuity, and the assumptions supporting goodwill and intangible-asset valuations.